The Swiss biotech has raised an impressive series A round which will go towards the development of T-cell engagers based on its unique technology, with an eye to reducing off-tumor activity.
CDR-Life Inc has completed a $76m series A financing to advance its pipeline of novel immuno-oncology candidates aiming for traditionally challenging targets while reducing off-tumor effects.
The round was co-led by Jeito Capital and RA Capital Management with Omega Fund Management acting as a third investor....
Multi-blockbuster falls short in a giant cell arteritis study.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
